CANbridge-UMass Chan Medical School Gene Therapy Research to be Presented at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting4 min read
To start with Analyze from the CANbridge UMass Chan Health care University Scarce Condition Gene Remedy Study Collaboration
BEIJING & CAMBRIDGE, Mass., May perhaps 04, 2022–(Company WIRE)–CANbridge Prescription drugs Inc., (“CANbridge,”1228.HK) a leading China-primarily based worldwide biopharmaceutical company dedicated to the exploration, progress and commercialization of transformative uncommon disorder and rare oncology therapies, announced that data from its gene remedy investigate arrangement with the Horae Gene Remedy Center, at the UMass Chan Health-related University, will be introduced at the ASGCT 25th Yearly Meeting, staying held in Washington D.C. from Could 16 – 19th. Scientists will existing results from an animal study discovering a novel 2nd-technology gene treatment for the likely cure of spinal muscular atrophy (SMA). This is the initially info to occur out of the CANbridge uncommon condition gene therapy analysis collaboration with the UMass Chan Medical Faculty, which is focused on developing gene treatment treatment options for neuromuscular circumstances with unmet professional medical requirements.
Title: Endogenous Human SMN1 Promoter-pushed Gene Alternative Increases the Efficacy and Protection of AAV9-mediated Gene Treatment for Spinal Muscular Atrophy in Mice
Category: Neurologic Health conditions I
Session Date and Time: Monday, May well 16, 5:30-6:30 PM
Authors: Qing Xie, Hong Ma, Xiupeng Chen, Yunxiang Zhu, Yijie Ma, Leila Jalinous, Qin Su, Phillip Tai, Guangping Gao, Jun Xie
Abstracts are readily available on the ASGCT website: https://annualmeeting.asgct.org
About the Horae Gene Treatment Middle at UMass Chan Health care College
The faculty of the Horae Gene Remedy Center is focused to developing therapeutic techniques for uncommon inherited disorder for which there is no remedy. We benefit from state of the art technologies to possibly genetically modulate mutated genes that generate disorder-leading to proteins or introduce a healthier copy of a gene if the mutation outcomes in a non-functional protein.
The Horae Gene Therapy Middle school is interdisciplinary, including members from the departments of Pediatrics, Microbiology & Physiological Devices, Biochemistry & Molecular Pharmacology, Neurology, Medicine and Ophthalmology. Medical professionals and PhDs operate together to handle the healthcare requirements of rare disorders, this sort of as Alpha 1-Antitrypsin Deficiency, Canavan Condition, Tay-Sachs and Sandhoff disorders, Retinitis Pigmentosa, Cystic fibrosis, Lou Gehrig’s disorder, TNNT1 nemaline myopathy, Rett syndrome, N-Gly 1 deficiency, Pitt-Hopkins syndrome, Marple Syrup Urine Sickness, Sialidosis, GM3 synthase deficiency, Huntington’s condition, ALS and other people. More widespread conditions these types of as cardiac arrhythmia and hypercholesterolemia are also investigated. The hope is to address a huge spectrum of diseases by a variety of gene therapeutic approaches. Furthermore, the University of Massachusetts Chan Professional medical School conducts medical trials on internet site and some of these trials are performed by the investigators at the Gene Therapy centre.
About CANbridge Prescription drugs Inc.
CANbridge Pharmaceuticals Inc. (“CANbridge,” 1228.HK) is a China-centered world-wide unusual ailment-concentrated biopharmaceutical business committed to the investigate, progress and commercialization of transformative rare disease and exceptional oncology therapies.
CANbridge has a extensive and differentiated pipeline of 13 drug assets with significant current market opportunity, targeting some of the most widespread scarce diseases and uncommon oncology.
These consist of Hunter syndrome (MPS II) and other lysosomal storage ailments (LSDs), complement mediated diseases, hemophilia A, metabolic conditions, exceptional cholestatic liver conditions which includes Alagille syndrome (ALGS), progressive familial intrahepatic cholestasis (PFIC) and biliary atresia (BA) as effectively as glioblastoma multiforme (GBM).
CANbridge strategically combines world wide collaborations and interior research to construct and diversify its drug portfolio and invest in next-technology gene remedy systems for exceptional ailment treatment options. CANbridge worldwide associates contain, but are not confined to, Apogenix, GC Pharma, Mirum, Wuxi Biologics, Privus, the College of Massachusetts Chan Health care University, the College of Washington University of Drugs, LogicBio and Scriptr.
For a lot more on CANbridge Prescription drugs Inc., please go to: www.canbridgepharma.com.
The forward-hunting statements made in this write-up relate only to the situations or data as of the date on which the statements are produced in this write-up. Other than as needed by legislation, we undertake no obligation to update or revise publicly any ahead-searching statements, whether as a end result of new facts, future events or in any other case, after the information on which the statements are built or to mirror the event of unanticipated functions. You must read through this short article entirely and with the knowing that our precise long term final results or efficiency may be materially diverse from what we anticipate. In this article, statements of, or references to, our intentions or those of any of our Directors or our Organization are designed as of the day of this write-up. Any of these intentions may well change in mild of future progress.
See resource model on businesswire.com: https://www.businesswire.com/news/household/20220503005199/en/
U.S. Trader Relations:
China Trader Relations
CANbridge Pharmaceuticals Inc.